The cholera toxin B subunit is a mucosal adjuvant for oral tolerance induction in type 1 diabetes.
When conjugated to various proteins, the nontoxic B-chain of cholera toxin (CTB) significantly increases the ability of these proteins to induce immunological tolerance after oral administration. Here, we investigated if a nonconjugated form of CTB enhances the induction of immune tolerance after oral insulin administration. Induction of immunological tolerance was studied after oral administration of insulin preparations in three mouse models; an insulin/ovalbumin coimmunization model, a model of virus-induced diabetes in transgenic RIP-LCMV-NP mice and in nonobese diabetic (NOD) mice serving as a model of spontaneous diabetes. In the immunization model, we demonstrate that mixing with CTB increases the tolerogenic potential of insulin, approximately 10 fold. Titration of the CTB concentration in this system revealed that an insulin : CTB ratio of 100 : 1 was optimal for the induction of bystander suppression. Further studies revealed that this insulin : CTB ratio also was optimal for the prevention of diabetes in a virus-induced, transgenic diabetes model. In addition, the administration of this optimal insulin-CTB preparation significantly prevented the onset of diabetes in old NOD mice with established islet infiltration. The data presented here demonstrate that CTB, even in its unconjugated form, functions as a mucosal adjuvant, increasing the specific tolerogenic effect of oral insulin.
Bregenholt
S
S
Islet Discovery Research, Novo Nordisk, Bagsvaerd, Denmark. sb@symphogen.com
Wang
M
M
Wolfe
T
T
Hughes
A
A
Baerentzen
L
L
Dyrberg
T
T
von Herrath
M G
MG
Petersen
J S
JS
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000284:Administration, Oral; D000818:Animals; D001324:Autoantigens / Q000008:administration & dosage / Q000276:immunology; D024201:Bystander Effect; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000209:etiology / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D018928:Immunity, Mucosal / Q000276:immunology*; D007114:Immunization; D007328:Insulin / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D007515:Islets of Langerhans / Q000276:immunology; D008216:Lymphocytic Choriomeningitis / Q000276:immunology; D008217:Lymphocytic choriomeningitis virus / Q000235:genetics; D051379:Mice; D008807:Mice, Inbred BALB C; D016688:Mice, Inbred NOD; D008822:Mice, Transgenic; D010047:Ovalbumin / Q000276:immunology; D014677:Pharmaceutical Vehicles; D011401:Promoter Regions, Genetic; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000276:Adjuvants, Immunologic; D001324:Autoantigens; D007328:Insulin; D014677:Pharmaceutical Vehicles; D010047:Ovalbumin; D002772:Cholera Toxin